These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 34273060)

  • 1. Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis.
    Kanbay M; Tapoi L; Ureche C; Tanriover C; Cevik E; Demiray A; Afsar B; Cherney DZI; Covic A
    Int Urol Nephrol; 2022 Apr; 54(4):827-841. PubMed ID: 34273060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective sodium-glucose cotransporter-2 inhibitors in the improvement of hemoglobin and hematocrit in patients with type 2 diabetes mellitus: a network meta-analysis.
    Luo Y; Bai R; Zhang W; Qin G
    Front Endocrinol (Lausanne); 2024; 15():1333624. PubMed ID: 38362282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis.
    Akbari A; Rafiee M; Sathyapalan T; Sahebkar A
    J Diabetes Res; 2022; 2022():7520632. PubMed ID: 35224108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
    Täger T; Atar D; Agewall S; Katus HA; Grundtvig M; Cleland JGF; Clark AL; Fröhlich H; Frankenstein L
    Heart Fail Rev; 2021 Nov; 26(6):1421-1435. PubMed ID: 32314085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of SGLT2i on 24-hour ambulatory blood pressure in patients with type 2 diabetes complicating hypertension: a meta-analysis].
    Tian L; Wang QY; Sun RM; Qi MM; Li YX; Gao X; Zhang LQ; Ma X; Shi H; Yu J; Bai F
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Oct; 49(10):1000-1011. PubMed ID: 34674438
    [No Abstract]   [Full Text] [Related]  

  • 6. The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials.
    Wang X; Fu R; Liu H; Ma Y; Qiu X; Dong Z
    Ann Palliat Med; 2021 Jun; 10(6):6467-6481. PubMed ID: 34118855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between sodium-glucose cotransporter 2 inhibitors and pioglitazone as additions to insulin therapy in type 2 diabetes patients: A systematic review with an indirect comparison meta-analysis.
    Cho YK; Kim YJ; Kang YM; Lee SE; Park JY; Lee WJ; Jung CH
    J Diabetes Investig; 2018 Jul; 9(4):882-892. PubMed ID: 29215196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.
    Tang H; Zhang X; Zhang J; Li Y; Del Gobbo LC; Zhai S; Song Y
    Diabetologia; 2016 Dec; 59(12):2546-2551. PubMed ID: 27628105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis.
    Li M; Yi T; Fan F; Qiu L; Wang Z; Weng H; Ma W; Zhang Y; Huo Y
    Cardiovasc Diabetol; 2022 Jul; 21(1):139. PubMed ID: 35879763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
    Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
    Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
    Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Am Heart J; 2021 Feb; 232():10-22. PubMed ID: 33214130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials.
    Li D; Liu Y; Hidru TH; Yang X; Wang Y; Chen C; Li KHC; Tang Y; Wei Y; Tse G; Xia Y
    Front Endocrinol (Lausanne); 2021; 12():619586. PubMed ID: 33815278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
    Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
    Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Mori Y; Duru OK; Tuttle KR; Fukuma S; Taura D; Harada N; Inagaki N; Inoue K
    J Clin Endocrinol Metab; 2022 Dec; 108(1):221-231. PubMed ID: 36217306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
    Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
    Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent renoprotection efficacy of sglt2 inhibitors in type 2 diabetes: systematic review and network meta-analysis.
    Hegde NC; Kumar A; Patil AN; Bhattacharjee S; Gamad N; Kasudhan KS; Kumar V; Rastogi A
    Acta Diabetol; 2023 Oct; 60(10):1311-1331. PubMed ID: 37322184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.